Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Health and hard-earned money traded on high-fat, poor-quality food

Dr. Sasson Moulavi, M.D., in a recent blog commented that food advertising is such a science that the average consumer does not have any chance of resisting when tempted by high-sugar, high-fat foods. In 2008, food and beverage companies spent $13.44 billion on advertising according to Advertising Age (6/09) and WPP's TNS Media Intelligence reporting.

5 Jan 2010

Vienna scientists develop new technique for producing H1N1 vaccines

Scientists in Vienna have developed a new technique for producing vaccines for H1N1, 'swine flu', based on insect cells. The research, published today in the Biotechnology Journal, reveals how influenza vaccines can be produced faster than through the traditional method of egg-based production, revealing a new strategy for the fight against influenza pandemics.

5 Jan 2010

Comprehensive studies on nanotechnology's HSE aspects vital

The advent of nanotechnology on the modern landscape has dramatically changed the shape, size, quality, cost, and efficiency of various applications. Nanotechnology is believed to be the most path-breaking technology, with this market expected to reach $1 trillion by 2015. The remarkable properties of the various nanomaterials have caught the attention of scientists, researchers, and manufacturers alike, and ongoing research activities are underway to harness their potential for the overall betterment of society.

5 Jan 2010

Positive results from Pearl Therapeutics' PT005 Phase 2a trial for COPD

Pearl Therapeutics Inc., a company developing high-quality combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from its first clinical trial in patients with chronic obstructive pulmonary disease (COPD).

5 Jan 2010

Elusys Therapeutics signs contract to complete the final development of Anthim

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has signed a contract potentially totaling up to $143 million to complete the final development, commercial manufacturing and licensure of Anthim, the company's late stage anthrax therapeutic.

5 Jan 2010

Tactx Medical acquired by Creganna

Creganna, a leading supplier of technologies and services to medical device and lifesciences companies today announced that it has acquired Avalon Medical Services Pte Ltd. which trades as Tactx Medical Inc.

4 Jan 2010

Carbon nanotube: A viable alternative for rapid DNA sequencing

Faster sequencing of DNA holds enormous potential for biology and medicine, particularly for personalized diagnosis and customized treatment based on each individual's genomic makeup.

4 Jan 2010

BiPro completes the requirements of NSF International's Athletic Banned Substances Certification Program

BiProUSA announced today that BiPro, an all natural whey protein isolate (dairy protein), has successfully completed the requirements of NSF International's Athletic Banned Substances Certification Program, Certified for Sport(TM).

4 Jan 2010

HIRU and HTDS announce finalization of MindUp BioResearch Division sale

This is a joint press release of Hiru Corporation (HIRU) and Hard to Treat Diseases (HTDS) - The two companies are pleased to announce the finalization and completion of the purchase and sale of the MindUp BioResearch Division. Details of the transaction completed on cash and stock basis can be found at the Pink Sheets web site www.pinksheets.com under the "filings" tab.

3 Jan 2010

TechPrecision presents strategic plan and outlook for 2010

TechPrecision Corporation (OTC Bulletin Board: TPCS) (“TechPrecision”, or “the Company”), a leading manufacturer of large-scale, high-precision machined metal fabrications with customers in the alternative energy, medical, nuclear, defense, aerospace and other commercial industries, today released the following open letter to shareholders reviewing the highlights of 2009 and providing an overview of the Company’s strategic plan and outlook for 2010.

3 Jan 2010

Anika Therapeutics acquires Fidia Farmaceutici subsidiary FAB

Anika Therapeutics, Inc. today announced that it has acquired Fidia Advanced Biopolymers, s.r.l. (“FAB”), a wholly-owned subsidiary of privately held Italian pharmaceutical company, Fidia Farmaceutici S.p.A. FAB provides hyaluronic acid-based (“HA”) products in several therapeutic areas including for the regeneration of connective and structural tissues damaged by injuries, aging or degenerative diseases.

3 Jan 2010

Pfizer provides update on Prevnar 13

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine.

31 Dec 2009

Vitro Diagnostics completes private placement of common stock and warrants to raise cash infusion

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced the completion of a private placement of its common stock and warrants representing an initial investment of $87,500, with an additional $87,500 should the warrants be exercised, by a group of private investors who previously purchased the Company’s stock at a 36% lower price, through a prior private placement. Please see the associated Form 8-K for additional details regarding this transaction.

31 Dec 2009

Dentists, chiropractors and physical therapists to see rise in revenues from mid-2010: IBISWorld

With the economy showing signs of recovery, industry research firm IBISWorld analyzed more than 700 industries to identify the winning sectors in the coming year.

30 Dec 2009

OSU researchers study biological and mechanical principles of cockroach to build robots

The sight of a cockroach scurrying for cover may be nauseating, but the insect is also a biological and engineering marvel, and is providing researchers at Oregon State University with what they call "bioinspiration" in a quest to build the world's first legged robot that is capable of running effortlessly over rough terrain.

29 Dec 2009

Elekta Crawley receives the World Class Manufacturer of the Year 2009 award

Elekta, the world-leading manufacturer of treatment solutions for cancer and brain disorders, has been awarded the prestigious World Class Manufacturing award by The Manufacturer magazine. The award was given in recognition of the quality work produced each year by Elekta manufacturing staff.

From Elekta 29 Dec 2009

Over 5,000 "Not Recommended" Internet drug outlets

On December 11, 2009, the National Association of Boards of Pharmacy(R) (NABP(R)) reached a bitter-sweet milestone in its ongoing review of Web sites selling prescription medications. NABP now lists more than 5,000 Internet drug outlets as Not Recommended. These sites -- 96% of the total number of sites reviewed -- have been found to be out of compliance with pharmacy laws and practice standards established in the United States to protect the public health.

29 Dec 2009

Successful RNA interference to turn off multiple genes raises hope for new liver disease treatments

Researchers at MIT and Alnylam Pharmaceuticals report this week that they have successfully used RNA interference to turn off multiple genes in the livers of mice, an advance that could lead to new treatments for diseases of the liver and other organs.

29 Dec 2009

Aeolus Pharmaceuticals reports financial results for three months and twelve months ended September 30, 2009

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months and twelve months ended September 30, 2009. The Company reported a net loss of $746,000, or $0.02 per share, for the three months ended September 30, 2009 compared to a loss of $1,055,000, or $0.03 per share, for the three months ended September 30, 2008.

28 Dec 2009

SemBioSys Genetics' Apo AI(Milano) program progress update

SemBioSys Genetics Inc. provided an update today on its progress on plant-produced Apo AI(Milano) in light of the Apo AI(Milano) license agreement between Pfizer Inc. and The Medicines Company, of Parsippany, New Jersey.

24 Dec 2009